Surgery Partners, Inc. (SGRY) · Aug 10, 2026 · Earnings

Revenue narrowly beats consensus as underlying case growth stays weak

Revenue narrowly beats consensus as underlying case growth stays weak

The quarter was modestly ahead of the market’s revenue bar. Net revenue was $848.9 million versus published consensus of approximately $847.0 million, a narrow beat of about 0.2%. Adjusted EBITDA reached $125.2 million, but the filing does not provide a comparable published consensus estimate, so the EBITDA result cannot be called a substantiated beat. (Q2 2026 Highlights)

MetricQ2 2026Comparison / expectation
Net revenue$848.9 millionPublished consensus: ~$847.0 million
Adjusted EBITDA$125.2 millionNo reliable external consensus disclosed
Same-facility revenue growth5.0%Filing metric
Same-facility surgical-case growth0.3%Filing metric
Same-facility rate growth4.8%Filing metric
Adjusted EBITDA margin14.7%14.9% excluding Idaho Falls

The quality of growth is less impressive than the headline. Same-facility revenue rose 5.0%, but surgical cases increased only 0.3%; nearly all the comparable-facility growth came from higher revenue per case, reflected in a 4.8% rate increase. That supports reported revenue, but it does not show strong demand or volume acceleration. (Q2 2026 Highlights)

Management gave investors no new upside to underwrite. Full-year revenue guidance of $3.35 billion–$3.45 billion, Adjusted EBITDA of at least $530 million, organic EBITDA growth of at least 4.2%, and same-facility revenue growth of at least 3.0% were reaffirmed rather than raised. (2026 Financial Outlook) The reaffirmation is broadly consistent with the quarter’s delivery, but it limits the positive read to execution versus expectations rather than an improved outlook.

The Idaho Falls divestiture makes the reported growth profile harder to read. The market generated $188.8 million of Q2 revenue and $26.9 million of Adjusted EBITDA, while the company presents continuing operations excluding it at $660.1 million of revenue and $98.3 million of EBITDA. The transaction reduces exposure to Medicaid and state-based supplemental revenue, but also removes a large revenue and EBITDA contributor; guidance explicitly excludes the transaction’s impact. (Q2 2026 Highlights; Idaho Falls Market Key Metrics & Business Mix Impacts)

Net: a narrow positive, not a clean acceleration signal. Revenue slightly exceeded the published bar and EBITDA was solid relative to the company’s quarterly pacing, but weak case growth, reliance on rate, and unchanged full-year guidance keep the result from qualifying as a broad upside surprise.

Original filing on SEC EDGAR

More Surgery Partners, Inc. news

Revenue narrowly beats consensus as underlying case growth stays weak | SGRY Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.